ATE237694T1 - Adenovirus vermittelter gentransfer in den gastrointestinaltrakt - Google Patents

Adenovirus vermittelter gentransfer in den gastrointestinaltrakt

Info

Publication number
ATE237694T1
ATE237694T1 AT92918712T AT92918712T ATE237694T1 AT E237694 T1 ATE237694 T1 AT E237694T1 AT 92918712 T AT92918712 T AT 92918712T AT 92918712 T AT92918712 T AT 92918712T AT E237694 T1 ATE237694 T1 AT E237694T1
Authority
AT
Austria
Prior art keywords
gastrointestinal tract
adenovirus
gene transfer
mediated gene
relates
Prior art date
Application number
AT92918712T
Other languages
English (en)
Inventor
Ronald G Crystal
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE237694T1 publication Critical patent/ATE237694T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92918712T 1991-08-20 1992-08-20 Adenovirus vermittelter gentransfer in den gastrointestinaltrakt ATE237694T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74737191A 1991-08-20 1991-08-20
PCT/US1992/007029 WO1993003769A1 (en) 1991-08-20 1992-08-20 Adenovirus mediated transfer of genes to the gastrointestinal tract

Publications (1)

Publication Number Publication Date
ATE237694T1 true ATE237694T1 (de) 2003-05-15

Family

ID=25004780

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92918712T ATE237694T1 (de) 1991-08-20 1992-08-20 Adenovirus vermittelter gentransfer in den gastrointestinaltrakt

Country Status (9)

Country Link
EP (1) EP0648271B1 (de)
JP (1) JP3534749B2 (de)
AT (1) ATE237694T1 (de)
AU (1) AU663725B2 (de)
CA (1) CA2115742A1 (de)
DE (1) DE69233013T2 (de)
DK (1) DK0648271T3 (de)
ES (1) ES2197145T3 (de)
WO (1) WO1993003769A1 (de)

Families Citing this family (501)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5651964A (en) * 1990-12-04 1997-07-29 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by the adenoviral EIA gene
US5643567A (en) * 1990-12-04 1997-07-01 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US5641484A (en) * 1990-12-04 1997-06-24 Board Of Regents, The University Of Texas System Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
WO1993021959A1 (en) * 1992-05-01 1993-11-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bystander effect tumoricidal therapy
EP1024198A3 (de) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenovirenvectors zur Gentherapie der Hämophilien
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
ATE221575T1 (de) * 1993-05-10 2002-08-15 Univ Michigan Gentransfer zu den pankreatischen epithelzellen
EP0710288B1 (de) * 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenovirale vektoren für die behandlung der hämophilie
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
CA2189067A1 (en) * 1994-04-28 1995-11-09 Gary J. Nabel Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
JPH10512243A (ja) * 1994-12-30 1998-11-24 カイロン コーポレイション 遺伝子送達ビヒクルの非外傷性投与
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
FR2732978B1 (fr) 1995-04-14 1997-05-30 Inst Nat Sante Rech Med Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
KR19990022184A (ko) * 1995-06-07 1999-03-25 스톤 스티븐 에프. 유전자구성물의 경구투여
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997035012A1 (en) 1996-03-20 1997-09-25 Board Of Regents, The University Of Texas System Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
FR2748753B1 (fr) * 1996-05-20 1998-08-14 Transgene Sa Nouveaux vecteurs adenoviraux pour la therapie genique
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
GB2318732A (en) 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
US6710036B2 (en) 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
EP1047784B2 (de) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigene aus neisseria meningitidis
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP2261338A3 (de) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
JPH11335269A (ja) 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US6410236B1 (en) 1999-09-01 2002-06-25 The Regents Of The University Of Michigan Correcting diastolic dysfunction in heart failure
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
JP2004508801A (ja) 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
EP2163626A1 (de) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Menschliches FGF-21 Gen und Genexpressionsprodukte
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
EP1854476A3 (de) 2000-02-09 2008-05-07 Bas Medical, Inc. Verwendung von Relaxin zur Behandlung von durch Vasokonstriktion bedingten Krankheiten
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
WO2001066595A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2003057926A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
ES2305087T3 (es) 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. Polinucleotidos relacionados con el cancer de colon.
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
KR100545945B1 (ko) 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
JP2004535765A (ja) 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
CA2434546C (en) 2001-01-12 2012-09-11 Chiron Corporation Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
EP1411770A4 (de) 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
EP2280074A3 (de) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
WO2003039491A2 (en) 2001-11-09 2003-05-15 Georgetown University Novel isoforms of vascular endothelial cell growth inhibitor
CN101670119A (zh) 2001-11-21 2010-03-17 利兰·斯坦福青年大学托管委员会 多核苷酸
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
AU2003218162B2 (en) 2002-03-15 2009-10-29 The Curators Of The University Of Missouri Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
EP2093233A1 (de) 2002-03-21 2009-08-26 Sagres Discovery, Inc. Neue Zusammensetzungen und Verfahren bei Krebs
US7384738B2 (en) 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US8518694B2 (en) 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
ZA200502612B (en) 2002-10-08 2007-07-25 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DK1569696T3 (da) 2002-11-21 2010-11-15 Bayhill Therapeutics Inc Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK2270048T3 (en) 2002-12-24 2016-01-18 Rinat Neuroscience Corp Anti-NGF antibodies and methods for their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CN101863930A (zh) 2003-01-06 2010-10-20 科里克萨有限公司 一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
JP2007524362A (ja) 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
BRPI0407375A (pt) 2003-02-19 2006-02-07 Rinat Neuroscience Corp Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP2353389B1 (de) 2003-04-21 2015-11-04 Epeius Biotechnologies Corporation Zusammensetzungen zur Behandlung von Erkrankungen
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20070073048A1 (en) 2003-05-15 2007-03-29 Ying Lian Hiv polynucleotides and polypeptides derived from botswana mj4
US7261544B2 (en) 2003-05-21 2007-08-28 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US20050036988A1 (en) * 2003-05-28 2005-02-17 Ruian Xu Compositions and methods for preventing and treating liver cirrhosis
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
AP2006003670A0 (en) 2003-12-23 2006-06-30 Rinat Neuroscience Corp Agonist anti-TRKC antibodies and methods using same
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
EP3372614B1 (de) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Verfahren zur schmerzbehandlung in knochenkrebs durch verabreichung eines ngf-antagonististen
AU2005327194B2 (en) 2004-07-09 2010-09-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus G glycoprotein
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
WO2006020684A2 (en) 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
EP1786473A4 (de) 2004-08-11 2008-11-19 Cedars Sinai Medical Center Behandlung von parkinson-krankheit und verwandter erkrankungen
EP1786474B1 (de) 2004-08-12 2011-06-01 Cedars-Sinai Medical Center Kombinierte gentherapie zur behandlung makroskopischer glioma
NZ553776A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
MX2007003850A (es) 2004-10-05 2007-11-21 Genzyme Corp Canula escalonada.
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
EP1865981A2 (de) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
EP1877087B1 (de) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
HUE041875T2 (hu) 2005-05-31 2019-06-28 Univ Colorado Regents Eljárás génbejuttatásra
EP1907425B1 (de) 2005-07-22 2014-01-08 Y's Therapeutics Co., Ltd. Anti-cd26-antikörper und verfahren zu ihrer verwendung
US7858590B2 (en) 2005-08-11 2010-12-28 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
EP3069731A1 (de) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonistische antikörper gegen calcitoningen-assoziiertes peptid und verfahren damit
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
EP2441846A3 (de) 2006-01-09 2012-07-25 The Regents Of the University of California Immunstimulierende Kombinationen aus TNFRSF, TLR, NLR, RHR, purinergischem Rezeptor, und Zytokin-Rezeptor-Antagonisten für Impfstoffe und die Tumorimmuntherapie
ES2388443T3 (es) 2006-03-29 2012-10-15 Dana-Farber Cancer Institute, Inc. Métodos y composiciones para inducir una respuesta inmune frente a VIH y modelos para ensayo
CN102164618A (zh) 2006-03-30 2011-08-24 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
CA2652703C (en) 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP2586790A3 (de) 2006-08-16 2013-08-14 Novartis AG Immunogene von uropathogenen Escherichia coli
WO2008066658A2 (en) 2006-11-03 2008-06-05 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
CN1966082B (zh) * 2006-11-03 2010-06-30 许瑞安 一种防治结直肠癌的基因药物及其制备方法和用途
US8883493B2 (en) 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
US20100261640A1 (en) 2007-04-10 2010-10-14 Branco Luis M Soluble and membrane anchored forms of lassa virus subunit proteins
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BRPI0822049B1 (pt) 2007-12-17 2021-11-16 Pfizer Limited Composiqao farmaceutica compreendendo anticorpo antagonista anti-ngf, kit e uso de um anticorpo antingf
HUE026846T2 (en) 2007-12-18 2016-08-29 Bioalliance Cv Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
EP3023502A1 (de) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
EP2303290B1 (de) 2008-06-25 2018-07-25 Mesoblast, Inc. Reparatur und/oder rekonstitution von bandscheiben
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
ES2550795T3 (es) 2008-11-20 2015-11-12 Mesoblast, Inc. Método para tratar o prevenir una disfunción pancreática
US8425922B2 (en) 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
JP2012516357A (ja) 2009-01-29 2012-07-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 神経学的障害を治療するための皮質全体に亘る高レベルの治療薬の分布方法
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP3263128A3 (de) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Zusammensetzungen zur immunisierung gegen staphylococcus aureus
HRP20250897T1 (hr) 2009-05-02 2025-09-26 Genzyme Corporation Genska terapija za neurodegenerativne poremećaje
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
JP5988961B2 (ja) 2010-04-28 2016-09-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 心筋細胞を発生させるための方法
MX2012013037A (es) 2010-05-10 2013-07-29 Univ California Composiciones de endorribonucleasa y metodos de uso de las mismas.
US20130150256A1 (en) 2010-06-11 2013-06-13 Jane Synnergren Novel micrornas for the detection and isolation of human embryonic stem cell-derived cardiac cell types
KR101891260B1 (ko) 2010-07-02 2018-08-24 메소블라스트, 아이엔씨. T-세포 매개된 면역 질환의 치료
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法
US9132173B2 (en) 2010-10-15 2015-09-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Expression vector for cholesterol 24-hydrolase in therapy of Huntington's disease
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012075243A2 (en) 2010-12-01 2012-06-07 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
KR101920277B1 (ko) 2011-06-03 2018-11-20 메소블라스트, 아이엔씨. 뇌졸중 증상을 치료하는 방법
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
CA2839341C (en) 2011-07-04 2020-12-15 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
US9642878B2 (en) 2011-09-09 2017-05-09 Mesoblast, Inc. Methods for increasing osteoblastic function
TWI495644B (zh) 2011-11-11 2015-08-11 Rinat Neuroscience Corp 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途
ES2724803T3 (es) 2011-12-16 2019-09-16 Univ Leland Stanford Junior Polipéptidos opsinas y métodos de utilización de los mismos
US9249224B2 (en) 2011-12-22 2016-02-02 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
EP3539563A1 (de) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Für cd22 spezifischer antikörper und verfahren zur verwendung davon
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
EP3722320A3 (de) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-komplement-c1s-antikörper und verwendungen davon
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CA2890483A1 (en) 2012-11-09 2014-05-15 Robert ARCH Platelet-derived growth factor b specific antibodies and compositions and uses thereof
CN111249455A (zh) 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
CN105358163B (zh) 2012-12-12 2020-09-11 麦瑟布莱斯特公司 内皮功能障碍和炎症的疾病的治疗
EP3521420A1 (de) 2013-01-08 2019-08-07 Genzyme Corporation Verwendung von inos-inhibitoren zur erhöhung der viralen ausbeute in kulturen
US9066966B2 (en) 2013-02-01 2015-06-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia
WO2014127148A1 (en) 2013-02-14 2014-08-21 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
AU2014236208B2 (en) 2013-03-14 2018-07-19 Genvivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
US9644215B2 (en) 2013-04-12 2017-05-09 The General Hospital Corporation AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors
CA2909706C (en) 2013-04-17 2023-02-14 Genzyme Corporation Use of an il17 inhibitor for treating and preventing macular degeneration
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
BR112015030356A2 (pt) 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
CA2916533C (en) 2013-06-25 2022-12-20 University Of Canberra Methods and compositions for modulating cancer stem cells
WO2015006641A2 (en) 2013-07-12 2015-01-15 Georgia State University Research Foundation, Inc. Methods and compositions for interference with dna polymerase and dna synthesis
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2919790C (en) 2013-08-02 2018-06-19 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
WO2015031686A1 (en) 2013-08-30 2015-03-05 Amgen Inc. High titer recombinant aav vector production in adherent and suspension cells
ES2851724T3 (es) 2013-09-18 2021-09-08 Epiaxis Therapeutics Pty Ltd Modulación de células madre
JP2016537995A (ja) 2013-11-05 2016-12-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新しいアルツハイマー病動物モデル
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
EP3835419A1 (de) 2013-12-12 2021-06-16 The Regents of The University of California Verfahren und zusammensetzungen zur modifizierung einer einzelsträngigen zielnukleinsäure
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
BR112016017817A2 (pt) 2014-02-06 2017-10-10 Genzyme Corp composições e métodos para o tratamento e a prevenção de degeneração macular
WO2015124546A1 (en) 2014-02-19 2015-08-27 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic Aav vectors for the treatment of ischemic and non-ischemic heart disease
BR112016019940A2 (pt) 2014-03-21 2017-10-24 Univ Leland Stanford Junior edição de genoma sem nucleases
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
WO2015195531A2 (en) 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PT3177640T (pt) 2014-08-08 2020-08-31 Univ Leland Stanford Junior Agentes pd-1 de alta afinidade e métodos de utilização
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
DK4074735T3 (da) 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
CA2972714A1 (en) 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US11118238B2 (en) 2014-12-17 2021-09-14 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
US11147887B2 (en) 2014-12-17 2021-10-19 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson disease
CN107405399B (zh) 2015-01-02 2022-02-08 武田药品工业株式会社 针对血浆激肽释放酶和因子xii的双特异性抗体
EP3054006A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten adeno-assoziierten viruspartikeln mittels mehrstufiger anionischer austauschchromatografie
EP3054007A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
EP3858992A1 (de) 2015-03-13 2021-08-04 The Jackson Laboratory Dreikomponentiges crispr/cas-komplexsystem und verwendungen davon
WO2016154010A1 (en) 2015-03-20 2016-09-29 Makidon Paul Immunogenic compositions for use in vaccination against bordetella
US11040113B2 (en) 2015-03-23 2021-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with Friedreich ataxia
JP6836999B2 (ja) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ アデノ随伴ウイルス変異体及びその使用方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
WO2016164371A1 (en) 2015-04-07 2016-10-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods for inducing cell division of postmitotic cells
TWI703159B (zh) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
AU2016258980B2 (en) 2015-05-05 2022-02-17 Mesoblast International Sàrl Potency assay
ES2959642T3 (es) 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
US20180161395A1 (en) 2015-06-12 2018-06-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical composition for the treatment of alzheimer's disease
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
ES2895652T3 (es) 2015-07-07 2022-02-22 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para expresar un polinucleótido de interés en el sistema nervioso periférico de un sujeto
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
AU2016297018B9 (en) 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
EP3331536A4 (de) 2015-08-03 2019-03-27 The Regents of The University of California Zusammensetzungen und verfahren zur modulierung der abhd2-aktivität
KR102438650B1 (ko) 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
CN117510633A (zh) 2015-09-02 2024-02-06 伊缪泰普有限公司 抗lag-3抗体
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
US20190048340A1 (en) 2015-09-24 2019-02-14 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
AU2016337525B2 (en) 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
CN115636880A (zh) 2015-10-23 2023-01-24 辉瑞有限公司 抗il-2抗体及其组合物和用途
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
US10669320B2 (en) 2015-11-18 2020-06-02 The Regents Of The University Of Michigan Mps1 and KNL1 phosphorylation system
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
US10406244B2 (en) 2015-12-02 2019-09-10 The Board Of Trustees Of The Leland Stanford Junior University AAV vectors with expanded packaging capacity
EP3384034B1 (de) 2015-12-02 2020-07-08 The Board of Trustees of the Leland Stanford Junior University Neue rekombinante kapside des adeno-associated virus mit erhöhtem tropismus für menschliche skelett- muskulatur
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
IL299616A (en) 2016-01-08 2023-03-01 Univ California Conditionally active heterodimeric polypeptides and methods of using them
PT3405215T (pt) 2016-01-19 2022-09-20 Univ California Métodos para o tratamento da doença de danon e outros transtornos da autofagia
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
JP6947739B2 (ja) 2016-02-16 2021-10-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 既存のヒト中和抗体に対して耐性である新規組換えアデノ随伴ウイルスカプシド
CA3014466A1 (en) 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
CU24649B1 (es) 2016-03-19 2023-02-13 Exuma Biotech Corp Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
LT3436051T (lt) 2016-03-31 2021-11-25 Spark Therapeutics, Inc. Kolonėlėmis pagrįstas visiškai keičiamo masto raav gavimo būdas
EP3452510A4 (de) 2016-04-04 2020-01-15 Bioverativ USA Inc. Anti-komplementfaktor-bb-antikörper und verwendungen davon
PL3455261T3 (pl) 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
WO2017222911A1 (en) 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
CA3030003A1 (en) 2016-07-08 2018-01-11 F1 Oncology, Inc. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
WO2018053035A1 (en) 2016-09-13 2018-03-22 The Jackson Laboratory Targeted dna demethylation and methylation
WO2018057648A1 (en) 2016-09-20 2018-03-29 The Board Of Trustees Of The Leland Stanford Junior University Peptide regulators of mitochondrial fusion and methods of use
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2018106753A1 (en) 2016-12-07 2018-06-14 The General Hospital Corporation Methods and compositions relating the treatment of tumors
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (de) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-zell-modulierende multimere polypeptide und verfahren zur verwendung davon
US20190367876A1 (en) 2017-01-18 2019-12-05 F1 Oncology, Inc. Methods of transducing and expanding immune cells and uses thereof
JP7280827B2 (ja) 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
WO2018138360A1 (en) 2017-01-28 2018-08-02 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Oxygen carrying blood substitutes and their use as delivery vehicles
JP7618386B2 (ja) 2017-01-30 2025-01-21 ブレインヴェクティス ポリグルタミン反復脊髄小脳失調症の処置におけるコレステロール２４－ヒドロキシラーゼ（ｈｙｄｒｏｌａｓｅ）のための発現ベクター
US20190345501A1 (en) 2017-02-07 2019-11-14 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
US20190359678A1 (en) 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
CA3054885A1 (en) 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anti-gitr antibodies and methods of use thereof
KR102879522B1 (ko) 2017-03-03 2025-11-04 엑수마 바이오테크, 코포레이션 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
US11510936B2 (en) 2017-03-24 2022-11-29 Inserm Methods and pharmaceutical composition for the treatment of neurodegenerative disease
US11827705B2 (en) 2017-03-28 2023-11-28 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
WO2018195555A1 (en) 2017-04-21 2018-10-25 The Board Of Trustees Of The Leland Stanford Junior University Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors
EP3615570A4 (de) 2017-04-25 2021-02-24 LBL Biotechnology Inc. Verwendung von il-20-antagonisten zur behandlung von augenerkrankungen
SG11201909856XA (en) 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
GB202209539D0 (en) 2017-06-13 2022-08-10 Bostongene Corp Systems and methods for identifying cancer treatments from normalized biomarker scores
WO2018232372A1 (en) 2017-06-16 2018-12-20 Protelica, Inc. Fibronectin binding domain chimeric antigen receptors and methods of use thereof
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
CN111315773A (zh) 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
CN111344403B (zh) 2017-09-15 2025-05-06 利兰斯坦福初级大学董事会 遗传工程细胞的多元性产生和条形码编制
CN111093715A (zh) 2017-09-18 2020-05-01 儿童医院医疗中心 强绝缘子和其在基因递送中的用途
EP3692370A2 (de) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Artikel und verfahren zur personalisierten krebstherapie
JP7369121B2 (ja) 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
EP3688011A4 (de) 2017-10-25 2021-11-24 The Administrators Of The Tulane Educational Fund Peptidzusammensetzungen und verfahren zu ihrer verwendung
CA3080120C (en) 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof
JP2021506251A (ja) 2017-12-14 2021-02-22 クリスパー セラピューティクス アーゲー 新規ｒｎａプログラム可能エンドヌクレアーゼ系、ならびにゲノム編集および他の適用におけるその使用
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
US12305185B2 (en) 2018-01-23 2025-05-20 Mount Spec Investments Pty Ltd Expression vector and method
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
PE20210708A1 (es) 2018-02-01 2021-04-16 Pfizer Anticuerpos especificos para cd70 y sus usos
AU2019228381B2 (en) 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
EP3758737A4 (de) 2018-03-02 2022-10-12 Kodiak Sciences Inc. Il-6-antikörper und fusionskonstrukte und konjugate davon
CN112040986A (zh) 2018-03-15 2020-12-04 Ksq治疗公司 用于改进的免疫疗法的基因调控组合物和方法
EP3765065A2 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Von sekretogranin v abgeleitete, antigene peptide und verwendungen davon zur diagnose und behandlung von diabetes typ 1
WO2019175384A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
US20210023209A1 (en) 2018-03-16 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
MA52074A (fr) 2018-03-19 2021-01-27 Bayer Healthcare Llc Nouveaux systèmes d'endonucléase à arn programmable et leurs utilisations
US11447769B2 (en) 2018-03-27 2022-09-20 The Trustees Of The University Of Pennsylvania Modified immune cells having enhanced function and methods for screening for same
EP3774853A1 (de) 2018-03-30 2021-02-17 The Board of Trustees of the Leland Stanford Junior University Neuartige kapside des rekombinanten adeno-assoziierten virus mit erhöhtem menschlichem pankreatischem tropismus
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
MX2020011386A (es) 2018-04-27 2021-01-29 Spacecraft Seven Llc Terapia genica para la degeneracion del snc.
WO2019219649A1 (en) 2018-05-14 2019-11-21 Vivet Therapeutics Gene therapy vectors comprising s/mar sequences
CN112839671A (zh) 2018-05-17 2021-05-25 明尼苏达大学董事会 抗药性免疫细胞及其使用方法
KR102602329B1 (ko) 2018-05-23 2023-11-16 화이자 인코포레이티드 Cd3에 특이적인 항체 및 이의 용도
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
AU2019299439C1 (en) 2018-07-03 2025-06-26 Sotio Biotech, Inc. Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
KR102918544B1 (ko) 2018-07-12 2026-01-27 로켓 파마슈티컬스, 리미티드 다논병을 치료하기 위한 유전자 요법 벡터
CN113039276A (zh) 2018-07-16 2021-06-25 密歇根大学董事会 核酸酶介导的核酸修饰
US20210309756A1 (en) 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
JP7456638B2 (ja) 2018-08-14 2024-03-27 ソティオ，リミティド ライアビリティ カンパニー クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用
US12275964B2 (en) 2018-08-22 2025-04-15 The Regents Of The University Of California Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
JP7450945B2 (ja) 2018-08-30 2024-03-18 テナヤ セラピューティクス， インコーポレイテッド ミオカルディンおよびａｓｃｌ１を用いた心細胞リプログラミング
US20210292791A1 (en) 2018-10-12 2021-09-23 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
JP7603580B2 (ja) 2018-10-15 2024-12-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用
US20220054597A1 (en) 2018-10-29 2022-02-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
AU2019375450A1 (en) 2018-11-07 2021-06-17 Vivet Therapeutics Codon-optimized ABCB11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)
WO2020097445A1 (en) 2018-11-09 2020-05-14 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
CN113710799B (zh) 2018-11-28 2024-11-12 克里斯珀医疗股份公司 用于在LNP中使用的编码CAS9的优化mRNA
US12157897B2 (en) 2018-12-04 2024-12-03 Catalent Pharma Solutions, Llc Vectors for protein manufacture
TWI856047B (zh) 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
WO2020132190A1 (en) 2018-12-21 2020-06-25 Multitude Inc. Antibodies specific to muc18
JP2022515916A (ja) 2019-01-02 2022-02-22 メゾブラスト・インターナショナル・エスアーエールエル 腰痛を治療するための方法
AU2020204809A1 (en) 2019-01-03 2021-07-29 Mesoblast International Sàrl Method for improving visual acuity
US12084500B2 (en) 2019-01-23 2024-09-10 New York University Antibodies specific to delta 1 chain of T cell receptor
JP2022524337A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 腫瘍抗原を標的とするｆｃ領域及び部分を含有する条件的に活性化された結合タンパク質
JP2022522405A (ja) 2019-03-06 2022-04-19 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
EP3935079A4 (de) 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-zell-modulierende antigen-präsentierende polypeptide und verfahren zur verwendung davon
MX2021010559A (es) 2019-03-07 2021-12-15 Univ California Polipéptidos efectores de crispr-cas y métodos de uso de estos.
SG11202109741VA (en) 2019-03-12 2021-10-28 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
EP3942026A1 (de) 2019-03-22 2022-01-26 Université de Paris Neue inhibitoren der lrrk2/pp1-interaktion
EP3947700A4 (de) 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-assoziiertes virus mit manipuliertem kapsid
JP7716623B2 (ja) 2019-04-02 2025-08-01 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
JP7624410B2 (ja) 2019-05-21 2025-01-30 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル レット症候群の治療におけるコレステロール ２４－ヒドロラーゼのための発現ベクター
CN113853206A (zh) 2019-05-23 2021-12-28 迈索布拉斯特国际有限公司 脑梗塞的功能恢复
JP7852185B2 (ja) 2019-07-02 2026-04-28 フンダシオン・パラ・ラ・インベスティガシオン・メディカ・アプリカダ ｃＰＬＡ２ｅ誘導剤及びその使用
US12205675B2 (en) 2019-07-03 2025-01-21 Bostongene Corporation Techniques for bias correction in sequence data
EP3997225A1 (de) 2019-07-10 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur behandlung von epilepsie
EP3997226A1 (de) 2019-07-11 2022-05-18 Tenaya Therapeutics, Inc. Umprogrammierung von herzzellen mit mikrornas und anderen faktoren
EP4003508A1 (de) 2019-07-31 2022-06-01 Memorial Sloan Kettering Cancer Center Perfusionsmodulierte tumordosismodellierung mit einzeldosis-strahlentherapie
US12612657B2 (en) 2019-08-16 2026-04-28 The Jackson Laboratory Extrachromosomal DNA labeling
WO2021062063A1 (en) 2019-09-26 2021-04-01 Chan Zuckerberg Biohub, Inc. Improved variants of tev protease for biotechnological applications
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
DK4034170T3 (da) 2019-10-23 2026-03-30 Cue Biopharma Inc Tgf-beta-polypeptider
US20230016983A1 (en) 2019-11-19 2023-01-19 lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Antisense oligonucleotides and thier use for the treatment of cancer
WO2021113736A1 (en) 2019-12-05 2021-06-10 Massachusetts Institute Of Technology Single-domain antibody to chloramphenicol
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021154079A1 (en) 2020-01-29 2021-08-05 Rijksuniversiteit Groningen Means and methods for modulating lipid metabolism
US11642407B2 (en) 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230103731A1 (en) 2020-03-02 2023-04-06 Tenaya Therapeutics, Inc. Gene vector control by cardiomyocyte-expressed micrornas
CN115811987A (zh) 2020-03-18 2023-03-17 纪念斯隆凯特琳癌症中心 抗神经酰胺抗体
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
AU2021265768B2 (en) 2020-04-27 2023-03-30 4D Molecular Therapeutics Inc. Adeno-associated variants, formulations and methods for pulmonary delivery
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
MX2022014943A (es) 2020-05-26 2023-03-08 Inst Nat Sante Rech Med Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
CN116529267A (zh) 2020-06-04 2023-08-01 肯乔克蒂生物技术股份有限公司 Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
US20230220391A1 (en) 2020-06-09 2023-07-13 Genethon CILP-1 Inhibitors for Use in the Treatment of Dilated Cardiomyopathies
CN116322790A (zh) 2020-06-09 2023-06-23 吉尼松公司 用于治疗扩张型心肌病的nrf2激活剂
WO2021250076A1 (en) 2020-06-09 2021-12-16 Genethon Treatment of genetic dilated cardiomyopathies
US20230235007A1 (en) 2020-06-15 2023-07-27 Ming-Che Shih Humanized ace2-fc fusion protein for treatment and prevention of sars-cov-2 infection
KR20230050336A (ko) 2020-07-10 2023-04-14 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) 뇌전증을 치료하기 위한 방법과 조성물
EP4182353A1 (de) 2020-07-17 2023-05-24 Janssen Biotech, Inc. Antiidiotypische antikörper gegen anti-klk2-antikörper
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
CA3190227A1 (en) 2020-07-30 2022-02-03 Pfizer Inc. Cells having gene duplications and uses thereof
CN116390773A (zh) 2020-08-06 2023-07-04 应用医学研究基金会 用于通过基因疗法治疗诸如阿尔茨海默病的Tau蛋白病的病毒颗粒
KR20230043869A (ko) 2020-08-07 2023-03-31 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
US20230295615A1 (en) 2020-08-07 2023-09-21 The Jackson Laboratory Targeted Sequence Insertion Compositions and Methods
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
US20230272433A1 (en) 2020-09-29 2023-08-31 Genethon Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof
US11781156B2 (en) 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
IL301255A (en) 2020-10-09 2023-05-01 UCB Biopharma SRL Nucleic acid structures, viral vectors and viral particles
BR112023006305A2 (pt) 2020-10-09 2023-05-09 Tenaya Therapeutics Inc Métodos e composições de terapia gênica com placofilina-2
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
US12254961B2 (en) 2020-12-04 2025-03-18 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
EP4277933A4 (de) 2021-01-14 2024-12-11 Senti Biosciences, Inc. Sekretierbare nutzlastregulierung
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
JP2024517745A (ja) 2021-04-29 2024-04-23 ボストンジーン コーポレイション 複合腫瘍組織における腫瘍細胞発現を推定するための機械学習技法
KR20240021211A (ko) 2021-06-10 2024-02-16 얀센 바이오테크 인코포레이티드 Klk2-gpi 융합 단백질에 대한 핵산 코딩, 재조합 세포 및 이의 용도
AU2022290382A1 (en) 2021-06-11 2023-11-23 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
EP4101928A1 (de) 2021-06-11 2022-12-14 Bayer AG Programmierbare typ-v-rna-endonukleasesysteme
CA3227875A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023012165A1 (en) 2021-08-02 2023-02-09 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
EP4144841A1 (de) 2021-09-07 2023-03-08 Bayer AG Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
WO2023049933A1 (en) 2021-09-27 2023-03-30 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
US20250011787A1 (en) 2021-10-21 2025-01-09 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads Retroelement-generated transcription factor decoys
EP4423286A1 (de) 2021-10-28 2024-09-04 UCB Biopharma SRL Nukleinsäurekonstrukte, virale vektoren und virale partikel
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
AU2022388928A1 (en) 2021-11-16 2024-05-16 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
EP4433512A4 (de) 2021-11-19 2025-12-31 Univ Pennsylvania Manipuliertes pan-leukozytenantigen cd45 zur erleichterung der car-t-zelltherapie
MX2024006506A (es) 2021-11-30 2024-08-14 Sanofi Pasteur Inc Vacunas basadas en vectores virales de metapneumovirus humano.
US20250051471A1 (en) 2021-12-13 2025-02-13 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-Abcb1 Antibodies
EP4453191A1 (de) 2021-12-23 2024-10-30 Bayer Aktiengesellschaft Neuartige programmierbare endonukleasesysteme für kleine v-rna
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
CA3249858A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation MACHINE LEARNING TECHNIQUES FOR CYTOMETRY
JP2025504081A (ja) 2022-02-01 2025-02-06 コーネル・ユニバーシティー フリードライヒ運動失調症に関連する心筋症の治療及び予防のための方法及び医薬組成物
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
EP4469586A1 (de) 2022-03-01 2024-12-04 Exuma Biotech Corp. Viruspartikel mit membrangebundener hyaluronidase
EP4499839A1 (de) 2022-03-25 2025-02-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Verfahren zur beurteilung der manipulierten retron-aktivität und verwendungen davon
EP4499822A1 (de) 2022-03-25 2025-02-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Rt-dna-fidelity- und retron-genomeditierung
WO2023183627A1 (en) 2022-03-25 2023-09-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
CN119403922A (zh) 2022-06-10 2025-02-07 拜耳公司 新的小型v型rna可编程内切核酸酶系统
EP4299739A1 (de) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Zusammensetzungen und verfahren zur genomeditierung
EP4299733A1 (de) 2022-06-30 2024-01-03 Inari Agriculture Technology, Inc. Zusammensetzungen, systeme und verfahren zum genomeditieren
WO2024005864A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
WO2024005863A1 (en) 2022-06-30 2024-01-04 Inari Agriculture Technology, Inc. Compositions, systems, and methods for genome editing
EP4551711A1 (de) 2022-07-08 2025-05-14 Cornell University Verfahren und pharmazeutische zusammensetzungen zur behandlung und prävention von morbus alzheimer
US20240029884A1 (en) 2022-07-15 2024-01-25 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
JP2025525569A (ja) 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024044659A1 (en) 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof
US20250243516A1 (en) 2022-08-24 2025-07-31 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Dual Cut Retron Editors for Genomic Insertions and Deletions
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4601743A1 (de) 2022-10-14 2025-08-20 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung von alpha-synukleinopathien
US20260109972A1 (en) 2022-11-09 2026-04-23 The Regents Of The University Of California High-Throughput Discovery of Multi-Partite CRISPR-Based Editors
AU2023380182A1 (en) 2022-11-18 2025-07-03 Kyoto Prefectural Public University Corporation Compositions for mitophagy induction and uses thereof
IL321270A (en) 2022-12-13 2025-08-01 Bayer Ag Engineered RNA-type programmable endonucleases and their uses
EP4646478A1 (de) 2023-01-06 2025-11-12 Institut National de la Santé et de la Recherche Médicale Intravenöse verabreichung von antisense-oligonukleotiden zur behandlung von schmerzen
JP2026504479A (ja) 2023-02-06 2026-02-05 ブルーロック セラピューティクス エルピー デグロン融合タンパク質並びにその産生及び使用の方法
EP4669330A1 (de) 2023-02-21 2025-12-31 Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzung zur behandlung des sanfilippo-syndroms vom typ iiib
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
JP2026509481A (ja) 2023-03-15 2026-03-19 京都府公立大学法人 ペプチド発現コンストラクトおよびその使用
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
EP4694916A1 (de) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Gentechnisch veränderte immunzellen zur behandlung von krebs in kombination mit il-2/il-15-rezeptor agonisten
WO2024220719A1 (en) 2023-04-18 2024-10-24 Crystal Ronald G Modified aav capsids for gene delivery
CN121335984A (zh) 2023-04-18 2026-01-13 康奈尔大学 用于治疗和预防阿尔茨海默病的方法和apoe药物组合物
WO2024220722A1 (en) 2023-04-18 2024-10-24 Cornell University Compositions and methods for tissue- specific expression of gene therapies
GB202307563D0 (en) 2023-05-19 2023-07-05 Univ King Abdullah Sci & Tech Methods and compositions
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
KR20260033032A (ko) 2023-06-29 2026-03-10 디스패치 바이오테라퓨틱스, 인크. 합성 시토카인 수용체
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
AU2024324215A1 (en) 2023-08-11 2026-02-26 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
CN121909039A (zh) 2023-09-04 2026-04-21 斯普莱斯生物有限责任公司 分裂内含肽用于治疗scn1a相关疾病的用途
WO2025076291A1 (en) 2023-10-06 2025-04-10 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
AU2024357861A1 (en) 2023-10-12 2026-04-23 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
US20260120879A1 (en) 2023-10-31 2026-04-30 Bostongene Corporation Machine learning technique for identifying ici responders and non-responders
WO2025111402A1 (en) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anti-amyloid beta antibodies and related compositions and methods thereof
EP4563586A1 (de) 2023-11-28 2025-06-04 Université Paris Cité Neue inhibitoren der lrrk2/pp1-interaktion
WO2025114512A1 (en) 2023-11-29 2025-06-05 Cnrs Dsi Therapeutic use of surf2 modulators
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025153705A1 (en) 2024-01-18 2025-07-24 Splicebio, Sl Use of split intein for the treatment of myo7a-associated disease
WO2025157848A1 (en) 2024-01-23 2025-07-31 Institut National de la Santé et de la Recherche Médicale Methods for the intravenous treatment of sanfilippo syndrome type iiib
US20250253011A1 (en) 2024-02-02 2025-08-07 Seven Bridges Genomics Inc. Techniques for improved tumor mutational burden (tmb) determination using a population-specific genomic reference
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025199352A2 (en) 2024-03-20 2025-09-25 Juno Therapeutics, Inc. Antibodies specific for solute carrier family 34 member 2 (slc34a2)
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2026006767A1 (en) 2024-06-28 2026-01-02 Dispatch Biotherapeutics, Inc. Tethered il-9/il-9r and related engineered cells and methods
WO2026013288A1 (en) 2024-07-12 2026-01-15 Splicebio, Sl Split intein for use in the treatment of cep290-associated disease
WO2026057767A1 (en) 2024-09-13 2026-03-19 Splicebio, Sl Use of split intein for the treatment of abca3-associated disease
WO2026069312A1 (en) 2024-09-24 2026-04-02 Yeda Research And Development Co. Ltd. Immune cells expressing an inducible therapeutic agent and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells

Also Published As

Publication number Publication date
EP0648271A4 (de) 1994-11-25
DE69233013D1 (de) 2003-05-22
JPH06510665A (ja) 1994-12-01
CA2115742A1 (en) 1993-03-04
ES2197145T3 (es) 2004-01-01
EP0648271B1 (de) 2003-04-16
AU2500692A (en) 1993-03-16
DE69233013T2 (de) 2004-03-04
JP3534749B2 (ja) 2004-06-07
AU663725B2 (en) 1995-10-19
WO1993003769A1 (en) 1993-03-04
DK0648271T3 (da) 2003-07-21
EP0648271A1 (de) 1995-04-19

Similar Documents

Publication Publication Date Title
ATE237694T1 (de) Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE69534878D1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
FI973309A0 (fi) Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
NO961639D0 (no) Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav
FI954966L (fi) Puutteellisia yhdistelmä-DNA-adenoviruksia kasvainten geeniterapiassa
ATE332363T1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
FI951138A0 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
CA2213343A1 (en) Chimeric adenoviral fiber protein and methods of using same
DE69535340D1 (de) Rekombinantes Adeno-assoziiertes Virus
BR9710654A (pt) Proteinas trifoliadas intestinais
HUT77049A (hu) Katepszin-02-fehérjék, -nukleinsavak és -ellenanyagok
ATE364083T1 (de) Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
FI962114A7 (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
FR2732346B1 (fr) Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications
NO974179L (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
NO951315L (no) Ökt produksjon av utsondrede proteiner fra rekombinante eukaryote-celler
EP1593742A3 (de) Rekombinante adenovirale Vektoren, die chimäre Fiberproteine exprimieren, für die zellspezifische Infektion
ZA979390B (en) Polypeptides comprising domains of the GAX protein which are involved in the repression of transcription and/or which interact with other proteins, corresponding nucleic acids and their uses.
ATE84315T1 (de) Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen.
NO910331D0 (no) Rekombinant plasmid, fremgangsmaate til dets fremstilling og anvendelse av plasmidet i produksjonen av proteiner.
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.
AU1209797A (en) Novel antigenic proteins of mycoplasmata, genes thereof, and recombinant vector and use of the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0648271

Country of ref document: EP

REN Ceased due to non-payment of the annual fee